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To share the experience of reviewing clinical data required for the licensing of follow-on biologic
products (biosimilar products and similar biotherapeutical products as EU and WHO terminology,
respectively) in Japan, the data packages of two follow-on biologics, “Somatropin BS s.c. [Sandoz]
(Omnitrope)” and “Epoetin alfa BS [JCR]”, which have been recently approved in Japan according to the
“Guidelines for the Quality, Safety and Efﬁcacy Assurance of Follow-on Biologics” published on March 4th
2009, are described. The clinical data package and indication of Somatropin BS/Omnitrope were
different in each country. In case of Epoetin alfa BS [JCR], non-clinical and clinical data-package was
different from those of erythropoietin biosimilar products approved in EU. Submission of post-marketing
surveillance plans for both products was required.
Even though there seem to be differences in data requirements by each national regulatory authority,
the accumulation of experience will provide the rationale and consensus on how to design the clinical
trials for follow-on biologics.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
Recently, the expiration of patents and/or data protection for the
ﬁrst major group of originator’s biotechnology-derived products
has promoted the development of biotechnology-derived products
that are designed to be ‘highly similar’ to a licensed innovator
product [1e4]. These highly similar biotechnology-derived prod-
ucts (namely follow-on biologics) rely for their licensing on accu-
mulated information regarding safety and efﬁcacy obtained from
the reference products. The clinical experience and established
safety proﬁle of the reference products should contribute to the
development of follow-on biologics. Therefore, the sponsor could
develop the products through the abbreviated approach of non-
clinical and clinical studies by using the experiences of the refer-
ence products. In fact, the amount and extent of data required for
the licensing of follow-on biologics is likely to be less than is nor-
mally required for the innovator products.
Japanese regulatoryauthority,MinistryHealth LaborandWelfare
(MHLW), has been confronted with the new challenge of regulating
follow-on biologics. To ensure the quality, safety and efﬁcacy of2; fax þ81 3 3506 9495.
rato), yamaguchi-teruhide@
ll rights reserved. The World Healthfollow-on biologic products, MHLW have published the “Guideline
for Quality, Safety and Efﬁcacy Assurance of Follow-on Biologics” on
March4th 2009 [5]. In EU,more than tenproducts alreadyhavebeen
marketed as biosimilar products following their biosimilar guide-
lines [6,7]. WHO, Canada and Korea also published the guidelines of
biosimilar [8e10]. These products have been differently named as
follow-on biologics (Japan), similar biological medical products
(biosimilar products in EU and Korea), subsequent entry biologics
(Canada) and similar biotherapeutic products (WHO). However, the
basic concept of these products is quite similar judging from each
guideline. For the development of follow-on biologics, the
manufacturingprocess shouldbe independentlywell-establishedas
for innovator products, and the quality attributes of follow-on bio-
logics shouldbewell-characterized, as required for thedevelopment
of new recombinant protein products (innovator products). In
addition, a high degree of similarity in quality attributes with the
reference product should be demonstrated. For the approval of
follow-on biologics, comparability with the reference products
should be demonstrated from both non-clinical and clinical studies.
Clinical studies should be designed based not only on the compa-
rability data in quality and non-clinical studies but also on the
relevant information about reference products.
Generally, the clinical studies to evaluate efﬁcacy and safety are
the main element in the development process of biotechnology-Organization has granted the Publisher permission for the reproduction of this article.
Table 1
Data-packages of Follow-on Biologics approved in Japan.
Guideline Somatropin BS EPO BS




Speciﬁcation B B B
Stability Long-term test B B B
Stress test D e B
Accelerated test D B B
Pharmacology Primary PD B B B
Safety Pharmacology e e B
Others e e e
PK ADME (non-clinical) D e B
BE (human) e e e
Others D e e
Toxicology Single-Dose Toxicity D D B
Repeat-Dose Toxicity B B B
Genotoxicity e e B




Local Tolerance D B B
Others D e e
Clinical Clinical Studies B B B
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period of time. Therefore, the abbreviation of some clinical studies
will help rapid development of follow-on biologics. The design of
clinical studies to evaluate the comparability of follow-on biologics
with the reference products is very important. In this review, expe-
riences of reviewing the follow-on biologics approved in Japan are
described, and then comparedwith other countries.We also address
the post-marketing surveillance of follow-on biologics in Japan.
2. Clinical data required in the guideline
Japanese guideline basically requires the comparative pharma-
cokinetics (PK) studies as is the case with other regions/countries.
Where available, it is important to select appropriate pharmaco-
dynamic (PD) markers to see clinical effect and to assess these in
comparability studies. Moreover, it is suggested that, based on the
analysis of the PK/PD studies, the clinical comparability between
the follow-on biologics and reference products will be evaluated.
In Japan, the comparability of follow-on biologics should be
evaluated through the clinical studies, as similar to the other
region. In case that PK/PD studies are sufﬁcient to assure compa-
rability of clinical efﬁcacy, additional clinical studies might be
omitted in Japan as well as in the EU, Korea (except Canada) as per
the WHO guideline.Table 2a
Clinical Data-package of Somatropin BS s.c.“Sandoz”(Omnitrope).
[PK/PD studies]
Study Number Study Design
EP00-106 A 3-arm cross-over trial to compare Omnitrope solution (5 mg
Omnitrope solution (10 mg/1.5 mL) vs Genotropin powder
EP00-104 A 3-arm cross-over trial to compare Omnitrope powder (5.8 m
Omnitrope solution (5 mg/1.5 mL) vs Genotropin powder
EP00-105 A 3-arm cross-over trial to compare Omnitrope powder (5.8 m
Omnitrope solution (10 mg/1.5 mL) vs Genotropin powder
EP2K-99-PhISUSA A placebo-controlled 2-arm cross-over trial of Omnitrope
powder (5.8 mg/vial)
EP2K-99-PhIUSA A 2-arm cross-over trial to compare Omnitrope powder
(5.8 mg/vial) vs Genotropin powder
EP2K-00-PhIAQ A 2-arm cross-over trial to compare Omnitrope powder
(5.8 mg/vial) vs Omnitrope solution (5 mg/1.5 mL)
B: Evaluation Data, D: Reference Data.In certain case, the safety proﬁle of follow-on biologics may
differ from that of the reference products due to the difference of
several factors, such as post-translational modiﬁcations, product-
and process-related impurities, and these may affect the immu-
nogenicity. In Japan, therefore, studies should be conducted to
evaluate antibody formation and other immunogenicity at an
appropriate stage of the clinical development, like the other region.
If reference products have more than one indication, the
important issue is whether follow-on biologics could be approved
for other indications where clinical studies have not been con-
ducted. Japanese guideline describes that it may be possible to
extrapolate from one indication to other indications of the inno-
vator product used as the reference product if the mechanism of
action is the same, like the other region.
3. Data-package of follow-on biologics approved in Japan
Two follow-on biologics, “Somatropin BS s.c. [Sandoz]
(Omnitrope)” and “Epoetin alfa BS [JCR]”, have been approved in
Japan according to the Japanese guidelines. Omnitrope has been
also approved in EU, Canada and USA. Several follow-on biologics
for erythropoietin have been approved in EU; Abseamed et. al. and
Retacrit et. al. In order to clarify the concept of regulatory pathway
to approval of follow-on biologics in other regulatory authorities,
the data-packages of follow-on biologics in Japan (Table 1) were
compared with those in other countries [11,12].
3.1. Data-package of Somatropin BS in Japan
The data-package of Somatropin BS [Sandoz] is comprised of
manufacturing process, characterization of quality attribute, spec-
iﬁcation, long-term and accelerated stability tests, pharmacology,
repeat-dose toxicity study, local tolerance and clinical study. Non-
clinical data-package of Somatropin BS [Sandoz] in Japan was the
same as that of Omnitrope in EU, Canada and USA (data not
shown).
Clinical data-package of Somatropin BS/Omnitrope approved
in each country was summarized in Tables 2a and 2b [11,13e15].
A three-period cross-over study in 54 Japanese healthy volunteers
comparing PK proﬁles of Somatropin BS 5mg, Somatropin BS 10mg
with Genotropin after a single s.c. dose was conducted for the
submission. In addition to this evaluation data, 5 PK studies and
Phase III trials in growth hormone deﬁciency (GHD) in pediatric
populations conducted in foreign countries were included as
supportive data in the clinical data-package for Japan. These
supportive data may be very useful to evaluate the comparability of
Somatropin BS [Sandoz]. Even though the PK studies comparingSubjects Japan EU Canada USA
/1.5 mL), 54 Healthy volunteers
(Japanese, Male)
B
g/vial), 36 Healthy volunteers D B
g/vial), 36 Healthy volunteers D B
12 Healthy volunteers D B B B
24 Healthy volunteers D B
24 Healthy volunteers D B B B
Table 2b
Clinical Data-package of Somatropin BS s.c.“Sandoz”(Omnitrope).
[PhIII studies]
Study Number Subjects Japan EU Canada USA
EP2K-99-PhIII/EP2K-00-PhIIIFo Sequential randomized open-label parallel study to compare
Omnitrope powder (5.8 mg/vial) vs Genotropin powder
89 GHD children D B B B
EP2K-00-PhIIIAQ (Part A) Sequential randomized open-label parallel study to compare
Omnitrope powder (5.8 mg/vial) vs Omnitrope solution
(5 mg/1.5 mL)
86 GHD children D B B B
EP2K-00-PhIIIAQ(Part B) Sequential study to conﬁrm the safety and efﬁcacy of
Omnitrope solution (5 mg/1.5 mL)
86 GHD children D B B B
EP2K-00-PhIIIb-E A single-arm study to conﬁrm long-term safety and
efﬁcacy of Omnitrope solution (5 mg/1.5 mL)
70 GHD children D B
EP2K-02-PhIIILyo A single-arm study to conﬁrm long-term safety and
efﬁcacy of Omnitrope powder (5.8 mg/vial)
51 GHD children D B B
B: Evaluation Data, D: Reference Data.
Table 4









Quality Manufacturing Process B B B B
Characterization B B B B
Speciﬁcation B B B B
Stability Lond-term test B B B B
Stress test D B ? ?
Accelerated test D B ? ?
Pharmacology Primary PD B B B B
Safety Pharmacology e B e e
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package for EU, the efﬁcacy between these products were
compared in Phase III trials in GHD pediatric group.
Indication of Somatropin BS/Omnitrope in each country is
summarized in Table 3. Phase III trials were conducted in GHD
pediatric group only, but it was possible to extrapolate from one
indication GHD in pediatric population to the other indications
such as Turner Syndrome and chronic renal insufﬁciency in Japan
since the mechanism of action was the same. The extrapolation
only granted after the re-examination periods (exclusive periods) of
indications on reference products were ﬁnished. Genotropin,
Norditropin, Humatrope, Saizen and Growjectwere approved
as new molecular entities (NMEs) in Japan. The indications of such
innovator products (NMEs) were based on clinical trial data of each
product. On the other hand, it is possible to extrapolate from one
indication to the other indications in follow-on biologics if the
mechanism of action is the same. In EU, Omnitrope has all indi-
cations of reference products Genotropin. In contrast to EU, the
extrapolation from the indication GHD in pediatric population was
limited to the GHD in adults in Canada. In USA, the extrapolation
from the indication GHD in pediatric population was limited to the
GHD in adults in USA when it was originally approved. Recently
PradereWilli syndrome, small for gestational age and idiopathic
short status were added to the indications of Omnitrope by using
the clinical data of other somatropin products in USA [16].
3.2. Data-package of Epoetin alfa BS in Japan
Epoetin alfa BS [JCR] was originally developed in Japan as a NME.
However, during product development, Japanese guideline for
follow-on biologics was published, so the licensure strategy for
Epoetin alfa BS [JCR] was changed to a follow-on biologic. There-
fore, non-clinical studies of Epoetin alfa BS [JCR] were conducted
following the requirement of new recombinant protein products
(Table 4) [12]. As for non-clinical toxicity studies, genotoxicity
study, reproductive and developmental toxicity studies were con-
ducted in addition to repeat-dose toxicity and local tolerance
studies which were conducted for Abseamed and RetacritwhichTable 3
Indication of Somatropin BS s.c.“Sandoz”(Omnitrope).
Indication Genotropin (Japan) Japan EU Canada USA
GHD in Pediatric B B B B B
Turner Syndrome B B B
Chronic renal insufﬁciency B B B
PradereWilli syndrome B B *
Small for gestational age B B *
GHD in Adults B B B B
Idiopathic Short Status *
*: new indication added 4 years after ﬁrst approval.have been approved as biosimilars in EU [17,18]. The comparative
repeated-dose toxicity study of Abseamed and Retacrit were
conducted with Eprex/Erypo as reference, while non-compara-
tive repeated-dose toxicity study was conducted for Epoetin alfa BS
[JCR]. In case of glycoprotein, it may be useful to compare the non-
clinical PK between the follow-on biologics and reference products
such as the case for Epeotin alfa BS [JCR] and Abseamed.
Table 5 shows the clinical data-package of Epoetin alfa BS [JCR].
Phase I study was an exploratory PK study assessing the PK proﬁle
of Epoetin alfa BS [JCR] in healthy volunteers. Two cross-over
studies comparing the safety and PK proﬁle of Epoetin alfa BS
[JCR] and reference product ESPO were conducted using both i.v.
and s.c. injection since ESPO (contain 750e3000 IU) has these two
routes of administration. One of them was a two period cross-over
study in 32 healthy volunteers after a single s.c. dose; the other was
a two period cross-over study in 24 heamodialysis patients with
renal anemia after a single i.v. dose. Phase II/III study was
a randomized, double-blind, parallel-group, multicentre design
study in 329 heamodialysis patients with renal anemia to compare
the efﬁcacy and safety between Epoetin Alfa BS [JCR] and ESPO.
1500 IU or 3000 IU was administrated to patients 2 or 3 times/week
for a total of 24 weeks. Primary endpoint was absolute change in
hemoglobin (Hb) level between the baseline period and the eval-
uation period. The 95% conﬁdence intervals of absolute change in
Hb level was within the acceptance range of 0.5w0.5 g/dL. Long-
term study was a single-arm study to conﬁrm long-term safety andOthers e e e e
PK ADME (non-clinical) D B B e
BE (human) e e e e
Others D e e e
Toxicology Single-Dose Toxicity D B e e
Repeat-Dose Toxicity B B B B
Genotoxicity e B e e
Carcinogenicity e e e e
Reproductive &
Developmental
e B e e
Local Tolerance D B B B
Others D e e e
Clinical Clinical Studies B B B B
Table 5
Clinical Data-package of Epoetin Alfa BS “JCR”.
Study Design Subjects Dosage
Ph I A placebo-controlled trial to
conﬁrm the safety & PK
24 Healthy volunteers Single Dose; iv 300 IU, 1500 IU, 3000 IU
Clinical
Pharmacology
A 2-arm cross-over trial comparing
the safety & PK of Epo BS vs ESPO
32 Healthy volunteers Single Dose; sc 1500 IU, 3000 IU
A 2-arm cross-over trial comparing
the safety & PK of Epo BS vs ESPO
24 Heamodialysis patients with
renal anemia
Single Dose; iv 1500 IU, 3000 IU
Ph II/III A double-blind trials comparing the
safety & efﬁcacy of Epo BS vs ESPO
329 Heamodialysis patients with
renal anemia
iv 1500 IU, 3000 IU 2w3 times/week
Long-term A single-arm study to conﬁrm long-term
safety and efﬁcacy of Epo BS
143 Heamodialysis patients with
renal anemia
iv 750w9000 IU 1w3 times/week
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renal anemia. There is no signiﬁcant difference between Epoetin
alfa BS [JCR] and ESPO regarding adverse events and serious
adverse events. Adverse events had not increased during the long-
term study. No anti-EPO antibody was identiﬁed.
While Phase III study of Retacrit was conducted in both
correction phase andmaintenance phase, clinical studies of Epeotin
alfa BS [JCR] were only conducted in patients on heamodialysis in
maintenance phase. Clinical data about patients on peritoneal
dialysis and in correction phase were not collected and clinical
study for anemia of prematurity has not been conducted even
though reference product ESPO has two indications, renal anemia
undergoing dialysis and anemia of prematurity. It was possible to
extrapolate from renal anemia undergoing hemodialysis to the two
indications of reference product since the mechanism of action is
the same.
4. Post-marketing surveillance in Japan
Data from pre-authorization clinical studies normally are
insufﬁcient to identify the all potential safety proﬁles, thus post-
marketing surveillance (PMS) of the safety proﬁle including
immunogenicity is required in Japan, like the other region. The
speciﬁc method and design of the PMS and risk management plan
should be submitted together with the application for approval
and be discussed with the regulatory authorities. The ﬁndings
obtained from the PMS should be reported to the regulatory
authority.
In case of Somatropin BS [Sandoz], patients’ data (w300) were
required to collect as PMS. Since the clinical studies on Turner
syndrome and chronic renal insufﬁciency had not been conducted,
the sponsor was required to collect clinical data for both indications
during PMS. Furthermore, the sponsor should analyze the lack of
efﬁcacy and immune reactions possibly due to expression of anti-
bodies against either somatropin or host cell protein.
In case of Epoetin Alfa BS [JCR], patients’ data (S500) should be
collected for 5 years as PMS. Since the clinical studies on PD
patients and anemia of prematurity had not been conducted, the
sponsor was required to collect clinical data from these patients
during PMS. Furthermore, the sponsor should analyze the lack of
efﬁcacy possibly due to expression of antibodies.
5. Conclusion
Even thought there are some differences of data-packages
submitted for each national regulatory authority, comparativePK/PD studies and/or comparative Phase III studies were required
or recommended in all countries/regions. In case that reference
products has more than one indication, the extent of the possible
extrapolation from one indication to other indications of the
reference products were different in each country/region. Since the
follow-on biologics are generally approved with the abbreviated
clinical data, safety data collected during PMS period is very
important. The accumulation of experiences will provide the
rationale and consensus on how to design the clinical trials for
follow-on biologics.
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